evaluate the pharmaceuticals and biotechnology company novo nordisk on glp-1's says Alzheimer's trial with older GLP-1 drug fails StockWatch: Lilly Narrows GLP-1 Revenue

These are not replacements for medication

New techniques for improving knowledge about intestinal peptides Despite the advances made in Mutt's laboratory, the isolation and purification of intestinal peptide hormones was time-consuming and expensive

Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA)

Diet matters

Oral GLP-1 formulations represent the fastest-growing drug class segment at 34.2% CAGR through 2035

These improvements may prove critical for women with PCOS should GLP-1 medications obtain the appropriate authorisation, as managing weight and insulin resistance can significantly improve overall health and fertility